<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2017-4-2-46-51</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-276</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЧЕСКИЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CANCER</subject></subj-group></article-categories><title-group><article-title>ПЕРВИЧНАЯ ДИАГНОСТИКА СЕПСИСА У ПАЦИЕНТОВ, ПОЛУЧАЮЩИХ ЛЕКАРСТВЕННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ: СРАВНЕНИЕ КРИТЕРИЕВ SIRS И SOFA</article-title><trans-title-group xml:lang="en"><trans-title>PRIMARY DIAGNOSIS OF SEPSIS IN PATIENTS RECEIVING MEDICINAL TREATMENT FOR ONCOLOGICAL DISEASE: COMPARISON OF SIRS AND SOFA CRITERIA</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курмуков</surname><given-names>Илдар Анварович</given-names></name><name name-style="western" xml:lang="en"><surname>Kurmukov</surname><given-names>Ildar A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., старший научный сотрудник, отдел функциональной диагностики, интенсивной терапии и реабилитации</p><p>Каширское шоссе, д. 23, Москва, 115478</p></bio><bio xml:lang="en"><p>MD, PhD, senior researcher, Department of Functional Diagnosis, Intensive Care and Rehabilitation</p><p>Kashirskoe sh., 23 Moscow, 115478</p></bio><email xlink:type="simple">kurmukovia@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашия</surname><given-names>Шалва Робертович</given-names></name><name name-style="western" xml:lang="en"><surname>Kashia</surname><given-names>Shalva R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., заведующий отделом функциональной диагностики, интенсивной терапии и реабилитации</p></bio><bio xml:lang="en"><p>MD, PhD, the head of Department of Functional Diagnosis, Intensive Care and Rehabilitation</p></bio><email xlink:type="simple">k_shalva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Обухова</surname><given-names>Ольга Аркадьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Obukhova</surname><given-names>Olga A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник, отдел функциональной диагностики, интенсивной терапии и реабилитации</p></bio><bio xml:lang="en"><p>MD, PhD, researcher, Department of Functional Diagnosis, Intensive Care and Rehabilitation</p></bio><email xlink:type="simple">obukhova0404@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пронина</surname><given-names>Анна Михайловна</given-names></name><name name-style="western" xml:lang="en"><surname>Pronina</surname><given-names>Anna M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отдел функциональной диагностики, интенсивной терапии и реабилитации</p></bio><bio xml:lang="en"><p>Department of Functional Diagnosis, Intensive Care and Rehabilitation</p></bio><email xlink:type="simple">belmar9@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юнаев</surname><given-names>Григорий Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Yunayev</surname><given-names>Grigory S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>отдел функциональной диагностики, интенсивной терапии и реабилитации</p></bio><bio xml:lang="en"><p>Department of Functional Diagnosis, Intensive Care and Rehabilitation</p></bio><email xlink:type="simple">garik_dr@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Российский онкологический научный центр им. Н. Н. Блохина» Минздрава России, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center» of the Russian Ministry of Health, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>08</day><month>06</month><year>2017</year></pub-date><volume>4</volume><issue>2</issue><fpage>46</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Курмуков И.А., Кашия Ш.Р., Обухова О.А., Пронина А.М., Юнаев Г.С., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Курмуков И.А., Кашия Ш.Р., Обухова О.А., Пронина А.М., Юнаев Г.С.</copyright-holder><copyright-holder xml:lang="en">Kurmukov I.A., Kashia S.R., Obukhova O.A., Pronina A.M., Yunayev G.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/276">https://transmed.almazovcentre.ru/jour/article/view/276</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность: Сепсис, осложняющий противоопухолевое лечение, оказывает существенное негативное влияние на продолжительность жизни и стоимость лечения онкологических больных. Быстрая диагностика является ключевым фактором уменьшения летальности при сепсисе. Для этого используются как критерии, основанные на наличии синдрома системной воспалительной реакции (SIRS), так и основанные на появлении органных нарушений у пациентов с инфекционным заболеванием (SOFA).</p></sec><sec><title>Цель исследования</title><p>Цель исследования: Определение полезности критериев SIRS и SOFA при их использовании в качестве скрининга сепсиса у больных, получающих противоопухолевую терапию по поводу распространенных злокачественных опухолевых заболеваний.</p><p>Материалы и методы исследования: Когортное ретроспективное исследование основных операционных характеристик методов диагностики сепсиса основано на результатах лечения 102 онкологических пациентов с инфекцией и различными осложнениями химиотерапии.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования: Сепсис был определен как достоверный у трети пациентов с инфекционными осложнениями.  Чувствительность критерия SIRS составила 0,79 (95% доверительный интервал (ДИ) 0,63-0,90), специфичность 0,41 (ДИ 0,30-0,53), точность теста 0,54 (ДИ 0,40-0,68). Чувствительность критерия SOFA составила 0,85 (ДИ 0,70-0,94), специфичность 0,68 (ДИ 0,56-0,76), а точность теста 0,74 (ДИ 0,60-0,85).</p></sec><sec><title>Заключение</title><p>Заключение: Чувствительность критериев SOFA по выявлению сепсиса у пациентов, получающих противоопухолевое лекарственное лечение, близка к чувствительности критериев SIRS при заметно более высокой специфичности и прогностичности. В связи с этим использование критерия SOFA у таких пациентов представляется в настоящее время более полезным. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction: Sepsis as a complication of chemotherapy has significant negative impact on life duration and cancer treatment cost. Immediate diagnostics is a key factor in reducing sepsis related mortality. Criteria based on systemic inflammatory response syndrome (SIRS) or sequential organ failure assessment (SOFA) are used for sepsis diagnosis alternatively.</p></sec><sec><title>Objective</title><p>Objective: determination of the usefulness of SIRS and SOFA criteria as screening for sepsis in patients receiving antitumor therapy for advanced malignant tumors.</p></sec><sec><title>Materials and methods</title><p>Materials and methods: A cohort retrospective study of the main operational characteristics of diagnostic methods for diagnosis of sepsis is based on the results of treatment of 102 cancer patients with infection and various chemotherapy-association complications.</p></sec><sec><title>Results</title><p>Results: Sepsis was defined in 33% of patients with infectious complications. The sensitivity of SIRS criteria was 0.79 (95% confidence interval (CI) 0.63-0.90), specificity 0.41 (CI 0.30-0.53), test accuracy 0.54 (CI 0.40- 0.68). The sensitivity of SOFA criteria was 0.85 (CI 0.70-0.94), specificity 0.68 (CI 0.56-0.76), test accuracy 0.74 (CI 0.60-0.85).</p></sec><sec><title>Conclusion</title><p>Conclusion: The sensitivity of the SOFA criteria for the detection of sepsis in patients receiving antitumor treatment is close to the sensitivity of the SIRS criteria with significantly higher specificity and predictive value. In this regard, the use of the SOFA criteria in such patients seems more useful.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>онкология</kwd><kwd>сепсис</kwd><kwd>операционные характеристики диагностического теста</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oncology</kwd><kwd>sepsis</kwd><kwd>operational characteristics of the clinical diagnosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Обухова О.А., Кашия Ш.Р., Курмуков И.А., Салтанов А.И. Гипергликемия при критических состояниях: возможные пути решения проблемы. Медицина неотложных состояний. 2011; №4: с. 49-53.</mixed-citation><mixed-citation xml:lang="en">Обухова О.А., Кашия Ш.Р., Курмуков И.А., Салтанов А.И. Гипергликемия при критических состояниях: возможные пути решения проблемы. Медицина неотложных состояний. 2011; №4: с. 49-53.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012; http://www.sccm.org/Documents/SSC-Guidelines.pdf</mixed-citation><mixed-citation xml:lang="en">Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012; http://www.sccm.org/Documents/SSC-Guidelines.pdf</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013(2); 381(9868): 774–775.</mixed-citation><mixed-citation xml:lang="en">Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013(2); 381(9868): 774–775.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Singer M., Deutschman CS, Seymour ChW, et al. JAMA. 2016; 315(8):801-810.</mixed-citation><mixed-citation xml:lang="en">Singer M., Deutschman CS, Seymour ChW, et al. JAMA. 2016; 315(8):801-810.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20:864–74.</mixed-citation><mixed-citation xml:lang="en">Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20:864–74.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31:1250–56.</mixed-citation><mixed-citation xml:lang="en">Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31:1250–56.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139–62.</mixed-citation><mixed-citation xml:lang="en">Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139–62.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nathan C, Ding A. Nonresolving inflammation. Cell. 2010; 140:871–82.</mixed-citation><mixed-citation xml:lang="en">Nathan C, Ding A. Nonresolving inflammation. Cell. 2010; 140:871–82.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. Journal of the American Statistical Association. 1927; 22, 209-212.</mixed-citation><mixed-citation xml:lang="en">Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. Journal of the American Statistical Association. 1927; 22, 209-212.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine.1998; 17, 857-872.</mixed-citation><mixed-citation xml:lang="en">Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine.1998; 17, 857-872.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
